Patents Assigned to Phaim Pharma Ltd
  • Combinations of Modalities for the Treatment of Diabetes
    Publication number: 20240058442
    Abstract: A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus by administering an effective amount of a fusion protein composition comprising a T-cell co-stimulation antagonist and a portion of an immunoglobulin molecule and an effective amount of a Type 1 diabetes autoantigen. The method includes, for example, administering a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule and a Type 1 diabetes autoantigen. Pharmaceutical compositions are also provided herewith.
    Type: Application
    Filed: March 14, 2023
    Publication date: February 22, 2024
    Applicant: Phaim Pharma Ltd.
    Inventor: Tihamer ORBAN
  • Diabetes Biomarkers
    Publication number: 20230333094
    Abstract: A new markers for insulin production decline in Type 1 diabetes has been found in the ratio the CD4 naïve (CD45RO?CD62L+) to central memory (CD45RO+CD62L+) and in the level of CD4 central memory T-cell subpopulations.
    Type: Application
    Filed: April 27, 2023
    Publication date: October 19, 2023
    Applicant: Phaim Pharma Ltd.
    Inventor: Tihamer ORBAN
  • CTLA4 fusion proteins for the treatment of diabetes
    Patent number: 11286303
    Abstract: A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus autoimmunity by administering an effective amount of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule is provided herewith. The CTLA4 molecule may be a fusion protein of a CTLA4 extracellular region and an immunoglobulin, such as abatacept.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: March 29, 2022
    Assignee: Phaim Pharma Ltd
    Inventor: Tihamer Orban
  • PSORIASIS AND OTHER AUTOIMMUNE DISEASES ANTIGEN IMMUNE MODULATOR (AIM) THERAPEUTIC PLATFORM
    Publication number: 20210404921
    Abstract: Provided are methods of preparing an immune cell sample from a subject having an autoimmune disorder, the method comprising: obtaining a tissue sample from the subject; and isolating a single immune cell in situ from the tissue sample using laser capture microdissection.
    Type: Application
    Filed: June 25, 2021
    Publication date: December 30, 2021
    Applicant: Phaim Pharma Ltd
    Inventors: Tihamer Orban, Jalahej Heyman, Nara Daubeney, Piers Daubeney
  • IMMUNOMODULATORY THERAPY FOR TYPE 1 DIABETES MELLITUS AUTOIMMUNITY
    Publication number: 20210353727
    Abstract: A composition for treating type 1 diabetes mellitus autoimmunity can include a therapeutically effective amount of two or more overlapping fragments of preproinsulin and a pharmaceutically acceptable carrier, wherein at least of the polypeptide fragments is antigenic.
    Type: Application
    Filed: June 2, 2021
    Publication date: November 18, 2021
    Applicant: PHAIM PHARMA LTD
    Inventors: TIHAMER ORBAN, JALAHEJ HEYMAN, NARA DAUBENEY, PIERS DAUBENEY
  • Immunomodulatory therapy for type 1 diabetes mellitus autoimmunity
    Patent number: 11040093
    Abstract: A composition for treating type 1 diabetes mellitus autoimmunity can include a therapeutically effective amount of two or more overlapping fragments of preproinsulin and a pharmaceutically acceptable carrier, wherein at least one of the polypeptide fragments is antigenic.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: June 22, 2021
    Assignee: Phaim Pharma Ltd
    Inventors: Tihamer Orban, Jalahej Heyman, Nara Daubeney, Piers Daubeney